Does Cilostazol Prevent Recurrent Stroke in Women?

Although dual antiplatelet therapy using cilostazol is associated with a lower risk of recurrent stroke in men, it has no significant benefit for women, a sub-analysis of CSPS.com results suggests.

Related Keywords

New Haven ,Connecticut ,United States ,Japan ,South Korea ,Haruhiko Hoshino ,Bristol Myers Squibb ,Pfizer ,International Stroke Conference ,Yale School Of Medicine ,Japan Cardiovascular Research Foundation ,National Institutes Of Health ,Boehringer Ingelheim ,Cilostazol Stroke Prevention Study Combination ,Tokyo Saiseikai Central Hospital ,Medscape Medical ,New Orleans ,Secondary Ischemic Stroke Prevention ,Cilostazol Stroke Prevention Study ,Medscape Medical News ,Adam De Havenon ,Yale School ,Otsuka Pharmaceutical ,National Institutes ,Stroke Conference ,Stroke ,Erebrovascular Accident ,Va Cerebrovascular Accident ,Ischemic Stroke ,Thromboembolism ,Antiplatelet Agent ,Aspirin ,Myocardial Infarction ,Peripheral Vascular Disease ,Recurrent Stroke ,Dyslipidemia ,Lipids ,Ipid Management ,Clinical Research ,Clinical Trials ,Linical Studies ,Diabetes Mellitus ,Hemorrhage ,Bleeding ,Sex Gender Difference ,Chronic Renal Failure ,Hronic Kidney Failure ,Hronic Ki ,